Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly

• DOI: 10.1002/hep.27014
• Publication Date: 2014-01-15T09:28:01Z
• Authors: Chien-Hsieh Chiang; Long-Teng Lee; Shou-Hung Hung; Wen-Yuan Lin; Hui-Fang Hung; Wei-Shiung Yang; Pei-Kun Sung; Kuo-Chin Huang
• Keywords: Adult; Male; Carcinoma, Hepatocellular; Liver Neoplasms; Taiwan; Middle Aged; 3. Good health; Diabetes Complications; 03 medical and health sciences; 0302 clinical medicine; Risk Factors; Multivariate Analysis; Humans; Female; Prospective Studies; Aged; Dyslipidemias

Limited data exist regarding metabolic risk factors for deaths from hepatocellular carcinoma (HCC) in aging individuals. We investigated the association between diabetes, dyslipidemia, and HCC mortality in those aged 40 years or more (middle-aged and elderly). In this prospective cohort study based on nationwide health screening units, we consecutively followed middle-aged and elderly participants who had no chronic hepatitis B or C virus infection and received health screening from January 1 1998 to December 31 2008. There were 235 deaths from HCC among 50,080 individuals, ascertained by validated death certificates and the national death registry. Diabetes (adjusted hazard ratio [HR], 3.38; 95% confidence interval [CI], 2.35 to 4.86) was positively associated with deaths from HCC. However, hypertriglyceridemia (HR, 0.38; 95% CI, 0.26 to 0.55) and hypercholesterolemia (HR, 0.50; 95% CI, 0.37 to 0.67) were inversely associated with HCC mortality. The above significant associations remained in the lag time analyses, applied to check for reverse causation. Metabolic syndrome, as defined by the American Heart Association / National Heart Lung Blood Institute criteria (HR, 0.63; 95% CI, 0.46 to 0.86) or by the International Diabetes Federation criteria (HR, 0.62; 95% CI, 0.43 to 0.89), was inversely associated with deaths from HCC, especially in men. Conclusion: Middle-aged and elderly individuals, once having diabetes, deserve HCC surveillance to reduce HCC mortality. More research is needed to elucidate why having baseline dyslipidemia relates to lower future HCC mortality. (Hepatology 2014;59:2207–2215)